Combination of isosorbide dinitrate and hydralazine in blacks with heart failure

Taylor, Anne L.; Ziesche, Susan; Yancy, Clyde W.

doi:10.1016/j.accreview.2005.02.045

Cited by 272 publications

(402 citation statements)

References 32 publications

Supporting

Mentioning

366

Contrasting

Unclassified

Order By: Relevance

“…In the African-American Heart Failure Trial, a fixed dose combination of isosorbide dinitrate and hydralazine reduced all-cause mortality and HF hospitalisations and improved quality of life, compared to placebo, in 1050 black patients with NYHA class III or IV HF on optimal medical treatment including diuretics and neurohormonal antagonists [54].…”

Section: Nitratesmentioning

confidence: 99%

Advanced chronic heart failure: A position statement from the Study Group on Advanced Heart Failure of the Heart Failure Association of the European Society of Cardiology

Metra

Ponikowski²,

Dickstein

et al. 2007

European J of Heart Fail

353

242

View full text Add to dashboard Cite

Therapy has improved the survival of heart failure (HF) patients. However, many patients progress to advanced chronic HF (ACHF). We propose a practical clinical definition and describe the characteristics of this condition.Patients that are generally recognised as ACHF often exhibit the following characteristics: 1) severe symptoms (NYHA class III to IV); 2) episodes with clinical signs of fluid retention and/or peripheral hypoperfusion; 3) objective evidence of severe cardiac dysfunction, shown by at least one of the following: left ventricular ejection fraction b 30%, pseudonormal or restrictive mitral inflow pattern at Dopplerechocardiography; high left and/or right ventricular filling pressures; elevated B-type natriuretic peptides; 4) severe impairment of functional capacity demonstrated by either inability to exercise, a 6-minute walk test distance b 300 m or a peak oxygen uptake b 12-14 ml/kg/min; 5) history of N1 HF hospitalisation in the past 6 months; 6) presence of all the previous features despite optimal therapy. This definition identifies a group of patients with compromised quality of life, poor prognosis, and a high risk of clinical events. These patients deserve effective therapeutic options and should be potential targets for future clinical research initiatives.

show abstract

Section: Nitratesmentioning

confidence: 99%

Advanced chronic heart failure: A position statement from the Study Group on Advanced Heart Failure of the Heart Failure Association of the European Society of Cardiology

Metra

Ponikowski²,

Dickstein

et al. 2007

European J of Heart Fail

353

242

View full text Add to dashboard Cite

show abstract

“…Bubb & Matthews, 2004) and treatment (such as the development of separate guidelines and therapies for different racial/ethnic groups; e.g. Williams et al, 2004;Taylor et al, 2004), and indirectly, in terms of the readiness to view racial/ethnic health disparities as innate and beyond the scope of public health interventions (e.g. Krieger, 2004).…”

Section: Genetic Explanations For Racial and Ethnic Disparities In Hementioning

confidence: 99%

Anthropological Insights Into the Use of Race/Ethnicity to Explore Genetic Contributions to Disparities in Health

Outram

Ellison

2005

J. Biosoc. Sci.

View full text Add to dashboard Cite

Summary.Anthropological insights into the use of race/ethnicity to explore genetic contributions to disparities in health were developed using in-depth qualitative interviews with editorial staff from nineteen genetics journals, focusing on the methodological and conceptual mechanisms required to make race/ethnicity a genetic variable. As such, these analyses explore how and why race/ethnicity comes to be used in the context of genetic research, set against the background of continuing critiques from anthropology and related human sciences that focus on the social construction, structural correlates and limited genetic validity of racial/ethnic categories. The analyses demonstrate how these critiques have failed to engage geneticists, and how geneticists use a range of essentially cultural devices to protect and separate their use of race/ethnicity as a genetic construct from its use as a societal and social science resource. Given its multidisciplinary, biosocial nature and the cultural gaze of its ethnographic methodologies, anthropology is well placed to explore the cultural separation of science and society, and of natural and social science disciplines. Anthropological insights into the use of race/ethnicity to explore disparities in health suggest that moving beyond genetic explanations of innate difference might benefit from a more even-handed critique of how both the natural and social sciences tend to essentialize selective elements of race/ethnicity. Drawing on the example of HIV/AIDS, this paper demonstrates how public health has been undermined by the use of race/ethnicity as an analytical variable, both as a cipher for innate genetic differences in susceptibility and response to treatment, and in its use to identify 'core groups' at greater risk of becoming infected and infecting others. Clearly, a tendency for biological reductionism can place many biomedical issues beyond the scope of public health interventions, while socio-cultural essentialization has tended to stigmatize 'unhealthy behaviours' and the communities where these are more prevalent.

show abstract

“…β 1 -blockers that modulate the endogenous production of nitric oxide (nebivolol) are another interesting option. Nebivolol seems to be more useful than other β-blockers in African American patients and those suspected of having decreased nitric oxide bioavailability as an underlying pathophysiology of disease [100], and, moreover, in seniors with heart failure [101]. Nonetheless, more research is needed to better assess the impact of these drugs on patients with COPD [102].…”

mentioning

confidence: 99%

Pharmacological modulation of β-adrenoceptor function in patients with coexisting chronic obstructive pulmonary disease and chronic heart failure

Matera

Martuscelli

Cazzola

2010

Pulmonary Pharmacology & Therapeutics

View full text Add to dashboard Cite

Combination of isosorbide dinitrate and hydralazine in blacks with heart failure

Cited by 272 publications

References 32 publications

Advanced chronic heart failure: A position statement from the Study Group on Advanced Heart Failure of the Heart Failure Association of the European Society of Cardiology

Advanced chronic heart failure: A position statement from the Study Group on Advanced Heart Failure of the Heart Failure Association of the European Society of Cardiology

Anthropological Insights Into the Use of Race/Ethnicity to Explore Genetic Contributions to Disparities in Health

Pharmacological modulation of β-adrenoceptor function in patients with coexisting chronic obstructive pulmonary disease and chronic heart failure

Contact Info

Product

Resources

About